Novartis, Amgen, Ionis shares slide after pelacarsen trial fail
Novartis, Amgen and Ionis shares are lower after Novartis’ pelacarsen failed to reduce heart risks, despite lowering harmful cholesterol Lp(a).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.